Efficacy and Safety of BEZ235 Compared to Everolimus in Patients With Advanced Pancreatic Neuroendocrine Tumors
Status:
Terminated
Trial end date:
2014-09-01
Target enrollment:
Participant gender:
Summary
This was a multicenter, open label, randomized phase II study to evaluate the efficacy and
safety of BEZ235 as compared to everolimus in patients with advanced, low to intermediate
grade pancreatic neuroendocrine tumor (pNET).